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ABSTRACT
Introduction: The objective of this study was to
assess efficacy and safety of repository corti-
cotropin injection (RCI) in subjects with active
rheumatoid arthritis (RA) despite treatment
with a corticosteroid and one or two disease-
modifying antirheumatic drugs (DMARDs).
Methods: All subjects received open-label RCI
(80 U) twice weekly for 12 weeks (part 1); only
those with low disease activity [LDA; i.e.,
Disease Activity Score 28 joint count and ery-
throcyte sedimentation rate (DAS28-ESR)
\3.2] were randomly assigned to receive either
RCI (80 U) or placebo twice weekly during the
12-week double-blind period (part 2). The pri-
mary efficacy endpoint was the proportion of
subjects who achieved LDA at week 12. Sec-
ondary efficacy endpoints included propor-
tions of subjects who maintained LDA during
weeks 12 through 24 and achieved Clinical
Disease Activity Index (CDAI) B 10 at weeks 12
and 24. Safety was assessed via adverse event
reports.
Results: Of the 259 enrolled subjects, 235
completed part 1; 154 subjects (n = 77 each for
RCI and placebo) entered part 2, and 127 (RCI,
n = 71; placebo, n = 56) completed. At week 12,
163 subjects (62.9%) achieved LDA and 169
(65.3%) achieved CDAI B 10 (both p\ 0.0001).
At week 24, 47 (61.0%) RCI-treated and 32
(42.1%) placebo-treated subjects maintained
LDA (p = 0.019); 66 (85.7%) RCI-treated and 50
(65.8%) placebo-treated subjects maintained
CDAI B 10 (p = 0.004). No unexpected safety
signals were observed.
Conclusions: RCI was effective and generally
safe in patients with active RA despite cortico-
steroid/DMARD therapy. By week 12,[60% of
patients achieved LDA, which was maintained
with 12 additional weeks of treatment. Most
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patients who achieved LDA maintained it for
3 months after RCI discontinuation.
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Key Summary Points
Why carry out this study?
Despite the availability of numerous
biologic and nonbiologic disease-
modifying antirheumatic drugs
(DMARDs) and despite using
glucocorticoids, many patients with
rheumatoid arthritis (RA) are unable to
achieve or maintain remission or low
disease activity (LDA) with these agents
and, as a result, may sustain irreversible
joint damage.
Repository corticotropin injection (RCI) is
a naturally sourced complex mixture of
adrenocorticotropic hormone analogues
and other pituitary peptides that
functions as an agonist of all five
melanocortin receptors and has several
potential mechanistic pathways that may
contribute to its therapeutic effects in RA.
The current study was undertaken to
confirm findings from previous small
open-label studies by assessing the
efficacy, safety, and tolerability of RCI in a
larger population of subjects with active
RA despite treatment with prednisone (or
an equivalent) and one or two
conventional synthetic DMARDs or one
biologic DMARD via a randomized,
double-blind, placebo-controlled
withdrawal trial with an open-label run-in
period.
What was learned from this study?
[60% of patients achieved LDA during
12 weeks of open-label RCI therapy,
which was maintained with 12 additional
weeks of RCI maintenance therapy; most
patients who achieved LDA maintained it
for 3 months after RCI discontinuation.
In patients with active RA despite
corticosteroid/DMARD therapy, RCI was
generally safe and was associated with
significant, durable, and beneficial effects
on disease activity.
INTRODUCTION
Rheumatoid arthritis (RA) is a systemic
autoimmune disease in which proinflammatory
cytokines act as mediators of synovial inflam-
mation, with resulting bone and cartilage
damage in multiple joints [1, 2]. Although the
distribution of RA varies by age and geographic
location, in developed countries the estimated
incidence and prevalence of RA in adults range
from 5 to 50 per 100,000 and 0.5–1.0%,
respectively [3]. A treat-to-target approach has
been advocated for RA, with the goal being
remission or low disease activity (LDA) if
remission cannot be obtained [4, 5]. The
cornerstones for treatment are conventional
synthetic disease-modifying antirheumatic drugs
(csDMARDs), biologic DMARDs (bDMARDs), and
targeted synthetic DMARDs, which suppress
inflammation that leads to eventual joint damage
[6]. If instituted early, effective DMARD therapy
may prevent irreversible joint damage and
improve function [6].
Rates of remission and clinical response in
DMARD-treated patients with RA vary widely
depending on the agents used, whether
monotherapy or combination therapy is
employed, the time point(s) assessed, and the
criteria for defining remission and response—
whether strict, such as the American Col-
lege of Rheumatology/European League Against
Rheumatism (ACR/EULAR) definitions [4, 5], or
less stringent, such as Disease Activity Score
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with 28 joint count and erythrocyte sedimen-
tation rate (DAS28-ESR)\2.6. Generally, at 1
year, estimates of remission range from 25%
with strict metrics to 55% with less stringent
metrics, and response rates to therapy range
from 35–65% [7]. Thus, despite availability of
numerous biologic and nonbiologic DMARDs,
substantial proportions of patients are unable to
achieve or maintain remission or LDA with
these agents and may sustain irreversible joint
damage and associated decline in their ability to
perform basic physical activity [6].
Corticosteroids are often used to rapidly con-
trol inflammation in patients with RA who are
initiating or changingDMARD therapy, but their
association with numerous adverse events (AEs)
limits their use [4, 5, 8]. Of particular con-
cern in patients with RA, corticosteroid use
for[ 3 months, particularly at a high dose, is
associatedwith rapid, persistent bone loss,which
contributes to increased risk of osteoporosis and
fractures [1]. Hence, additional treatment
options for patients with RA are needed.
Repository corticotropin injection (RCI;
Acthar Gel) is a naturally sourced complex
mixture of adrenocorticotropic hormone ana-
logues and other pituitary peptides. As an ago-
nist of all five melanocortin receptors (MCRs),
RCI has several potential mechanistic pathways
that may contribute to its therapeutic effects in
RA [9, 10]. Results from preclinical studies sug-
gest several nonsteroidogenic pathways for RCI
that may affect inflammation and immune
regulation. Activation of MCR1 has been shown
to affect the nuclear factor-jB (NF-jB) pathway,
leading to downregulation of inflammatory
cytokines [11–13]. Multiple cells of the immune
system express MCR1, MCR3, and/or MCR5,
suggesting they have additional roles in medi-
ating inflammation [11, 14, 15]. Further, MCR1
and MCR5 are present on human articular
chondrocytes and rheumatoid synovial fibrob-
lasts, which are involved in the chronic
immune response in RA [11, 16]. All five MCRs
are expressed on osteoclasts and osteoblasts
[17, 18], a finding that could have implications
for the bone resorption associated with RA
[11, 14, 15, 18].
The evidence for the clinical effectiveness of
RCI in patients with RA was suggested in small
open-label studies [19–21]. The current study
was undertaken to confirm these findings in a
larger population via a randomized, double-
blind, placebo-controlled withdrawal trial with
an open-label run-in period. Our objective was
to assess the efficacy, safety, and tolerability of
RCI in subjects with active RA despite treatment
with prednisone (or an equivalent) and one or
two csDMARDs or one bDMARD.
METHODS
Study Design
The design of this two-part multicenter, ran-
domized, placebo-controlledwithdrawal study is
shown in Fig. 1. All enrolled subjects received
open-label RCI (1 ml, 80U) subcutaneously twice
weekly for 12 weeks (part 1), a dosage that pre-
vious studies suggest is effective [20, 21]. Subjects
were then assessed for treatment response using
the DAS28-ESR, with thresholds of 2.6, 3.2, and
5.1 suggesting remission, LDA, and high disease
activity, respectively [22, 23]. Subjects who
achievedLDA (DAS28-ESR\ 3.2) atweek12were
randomly assigned to receive either subcuta-
neous RCI (1 ml, 80 U) or matching placebo
(1 ml) twice weekly during the 12-week, double-
blind withdrawal period (part 2).
The study was conducted at 60 centers in
four countries (see electronic supplementary
material for details on study centers) from
November 7, 2016, to February 13, 2019, in
accordance with the principles and require-
ments of the Declaration of Helsinki, Good
Clinical Practices, and clinical trial registration
(clinicaltrials.gov identifier NCT02919761). All
investigators obtained institutional review
board/independent ethics committee approval.
All subjects provided informed consent (in-
cluding consent for publication) before any
study procedures were performed.
Key Study Entry Criteria
Individuals eligible for participation included
men and nonpregnant, nonlactating women
aged C 18 years who met the 2010 ACR/EULAR
criteria [24] for having RA that was active,
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defined as DAS28-ESR[ 3.2, despite treatment
with a stable dose (5–10 mg) of prednisone (or
equivalent) and one or two csDMARDs or one
bDMARD (Table S1 in the electronic supple-
mentary material). Subjects who were taking
nonsteroidal anti-inflammatory drugs were
required to be on a stable dose for 4 weeks
before screening and remain on a stable dose
throughout study participation.
Individuals were ineligible for participation
if they had any rheumatic autoimmune disease
or inflammatory joint disease other than RA,
had a history of using adrenocorticotropic hor-
mone (ACTH) preparations for RA or a history
of sensitivity to ACTH preparations, or had
known contraindications to RCI use; had used
any investigational treatment for RA or any
biologic investigational agent in the 24 weeks
before the first dose of study drug, any non-
biologic investigational agent within 6 weeks
before the first dose of study drug, B cell-medi-
ated therapies in the 24 weeks before screening,
or intraarticular corticosteroids within 14 days
before screening; or had type 1 or type 2 dia-
betes mellitus, a history of chronic active hep-
atitis or tuberculosis, a solid tumor or
hematologic malignancy, drug/alcohol abuse,
or a clinically significant infection.
The use of intraarticular steroids; live or
attenuated vaccines; enteral or parenteral
immunosuppressive medications; or an investi-
gational drug, device, or procedure adminis-
tered as part of a research study was not
permitted during the trial.
Procedures and Interventions
Within 28 days after screening, enrolled sub-
jects underwent baseline evaluations, which
included calculation of their DAS28-ESR. At the
baseline visit, all subjects received their first
dose of open-label RCI (1 ml, 80 U) and were
observed for 1 h afterward. Subsequent open-
label RCI doses were administered twice weekly
at home by the subject or caregiver. Subjects
returned to the study center at weeks 4, 8, and
12 (part 1) for efficacy and safety assessments.
At week 12, subjects who had achieved LDA
(DAS28-ESR\3.2) were randomly assigned (in
a 1:1 ratio) to receive either 1 ml (80 U) of RCI
or 1 ml of placebo subcutaneously twice weekly
during the 12-week double-blind period (part
2), which was designed to evaluate mainte-
nance of response to therapy. Subjects who did
not achieve LDA at week 12 were discontinued
from further study participation.
Fig. 1 Study design. LDA low disease activity, R randomization, RCI repository corticotropin injection
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During the double-blind period, subjects
returned to the study center at weeks 16 and 24
for efficacy and safety assessments. Blood and
urine samples for analysis of bone turnover
markers were collected at weeks 12 and 24. At
the follow-up visit, 28 days after the final dose
of study drug, safety assessments were
completed.
Bone turnover markers were analyzed by
Eurofins Central Laboratory (Breda, The Nether-
lands). C-terminal crosslinking telopeptide
(CTX), CTX-I, andN-terminal propeptide of type
I collagen (PINP) were evaluated via electro-
chemiluminescence immunoassay (Roche Diag-
nostics, Indianapolis, IN, USA); enzyme-linked
immunosorbent assay was used to assess CTX-II
(Immunodiagnostic Systems, East Boldon, UK),
osteoprotegerin (OPG; Quidel, San Diego, CA,
USA), and soluble receptor activator of NF-jB
ligand (sRANKL; BioVendor, Karasek, Czech
Republic). Creatinine was evaluated via Jaffe
reaction using alkaline picrate (Roche Diagnos-
tics, Indianapolis, IN, USA), and creatinine-ad-
justed CTX-II (CTX-II CRT) was calculated using
the following formula:
CTX-II CRT ng=mmolð Þ
¼ 1000  CTX-II lg=Lð Þ=creatine mmol=Lð Þ:
Randomization and Blinding
Almac Clinical Technologies generated the
randomization sequence, which used a block
size of 4 and a 1:1 treatment allocation ratio.
Four hundred randomization numbers (200 per
treatment group) were generated, and random-
ization activities were conducted via the IXRS
(interactive phone/web response system). A
dummy subject randomization list was used for
IXRS development and for Almac/client user
acceptance testing. Except for those who pre-
pared the randomization protocol and those
involved in study drug preparation, all parties
were blinded to subjects’ treatment conditions
during the double-blind period.
Endpoints
The primary efficacy endpoint was the propor-
tion of subjects who achieved DAS28-ESR\ 3.2
at week 12 in part 1 of the study. Secondary
efficacy endpoints included the proportion of
subjects who maintained DAS28-ESR\3.2 from
week 12 through week 24; time to disease
activity flare (as defined below) from weeks 12
through 24; the proportion of subjects with
Clinical Disease Activity Index (CDAI) LDA (i.e.,
CDAI B 10) [25] at weeks 12 and 24; and the
proportion of subjects who met ACR criteria for
20% improvement (ACR20) at weeks 12 and 24.
For weeks 13 through 23, disease activity flare
was defined as meeting one of the following
criteria: (1) DAS28-ESR\3.2 and an increase of
1.2 from week 12; (2) DAS28-ESR C 3.2 and an
increase of[ 0.6 from the week 12 assessment
sustained over two consecutive visits; or (3)
DAS28-ESR C 3.2 and an increase of[1 from
the week 12 assessment at a single visit. Criteria
1 and 2 were based on validated criteria for RA
flares [26, 27]; the third criterion was developed
on the basis of the first two criteria, with slight
modification for more stringency to capture
potential flares not meeting criterion 1 or 2.
Exploratory endpoints included the propor-
tions of subjects who achieved ACR50 and
ACR70 responses at weeks 12 and 24 (with week
24 evaluated post hoc); the proportion of sub-
jects with DAS28-ESR\2.6 at weeks 12 and 24;
and changes from baseline to weeks 12 and 24
in scores on the Health Assessment Question-
naire-Disability Index (HAQ-DI) [28], Func-
tional Assessment of Chronic Illness Therapy-
Fatigue (FACIT-F) [29], and Work Productivity
and Activity Impairment (WPAI) scale [30].
Changes from baseline to weeks 12 and 24 in
key markers of bone turnover (i.e., CTX, CTX-I,
CTX-II, CTX-II CRT, PINP, OPG, sRANKL) were
also evaluated as exploratory endpoints. Safety
endpoints included AEs, vital signs, and labo-
ratory test results, evaluated by study period
and over the entire study.
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Statistical Analysis
Screening of 360 subjects and enrollment of 232
were expected. An estimated 45% of enrolled
subjects were expected to achieve DAS28-
ESR\ 3.2 at week 12 and continue on to be
randomly assigned in part 2 of the study. On
the basis of results from previous studies
[31, 32], 80% of the RCI group and 50% of the
placebo group were predicted to maintain LDA
through week 24 (part 2). A sample size of 52
subjects per treatment group during part 2 was
determined to provide 90% power to detect a
difference between treatment groups using a
two-sided, two-sample comparison of propor-
tions at the significance level of 0.05.
The safety population included all enrolled
subjects who received C 1 dose of study drug.
All subjects from the safety population who
contributed any efficacy data to the study
comprised the modified intent-to-treat (mITT)
population, which was used for all efficacy
analyses. All safety analyses were conducted
using the safety population.
Data for all study variables were summarized
via descriptive statistics. For the primary end-
point, the proportion of subjects with DAS28-
ESR\ 3.2 at week 12 (part 1), along with a two-
sided 95% confidence interval (CI), was calcu-
lated. The study was deemed successful if the
lower bound of the 95% CI was C 10%.
The proportions of subjects with LDA
defined by CDAI scores B 10 at week 12 and the
proportions of subjects who met ACR20,
ACR50, or ACR70 criteria at week 12 were ana-
lyzed using the same method as the primary
endpoint. Changes from baseline to week 12 for
the DAS28-ESR, HAQ-DI, FACIT-F, WPAI, tender
joint count, swollen joint count, and bone
turnover markers were evaluated with one-
sample t tests.
The proportions of subjects who maintained
DAS28-ESR\ 3.2 during part 2 (withdrawal
phase, weeks 12–24) were compared across
treatment groups using a Pearson’s Chi-square
test, and the proportions of subjects who
maintained DAS28-ESR\2.6 and CDAI scores
B 10 and who met ACR20, ACR50, or ACR70
criteria were evaluated similarly. The time to
disease activity flare in part 2 was analyzed
using a log-rank test. Changes from baseline to
week 24 for the DAS28-ESR, HAQ-DI, FACIT-F,
WPAI, tender joint count, swollen joint count,




Of 259 enrolled subjects, 235 completed the
open-label period and 127 completed the ran-
domized, placebo-controlled, double-blind
withdrawal period (Fig. 2). Subject demograph-
ics and baseline characteristics are shown in
Table 1.
Efficacy: Open-Label Period
At week 12, 163 subjects [62.9% (95% CI
57.3–69.1%)] achieved DAS28-ESR\ 3.2, the
study’s primary endpoint (p\0.0001; Fig. 3a).
Figure 3c shows mean DAS28-ESR over time
during the open-label period; mean change
from baseline to week 12 was - 2.75 [standard
deviation (SD), 1.45; p\0.001]. Also at week
12, 169 subjects (65.3%) reached LDA, as
defined by a CDAI score B 10 (Fig. 3e), and
83.0% of subjects achieved ACR20, 62.5%
achieved ACR50, and 30.1% achieved ACR70
(all p\0.0001; Fig. 3g). Forty-nine subjects
(18.9%) achieved DAS28-ESR\ 2.6 (i.e., remis-
sion) at week 12. Levels of C-reactive protein did
not change substantially (Figure S1a in the
electronic supplementary material). Significant
decreases from baseline in the number of tender
and swollen joints were observed (Figure S2a in
the electronic supplementary material).
Patient-Reported Outcomes: Open-Label
Period
During part 1, open-label RCI therapy led to
significant improvements from baseline in
HAQ-DI (Figure S3a in the electronic supple-
mentary material) and FACIT-F (Figure S4a in
the electronic supplementary material) scores,
as well as significant decreases from baseline in
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the percentages of work time missed, impair-
ment while working, overall work impairment,
and activity impairment, as assessed via the
WPAI (Figure S5a in the electronic supplemen-
tary material).
Bone Turnover Markers: Open-Label
Period
Most bone turnover markers were stable during
the open-label period (Table 2), suggesting a
minimal further impact of RCI on bone meta-
bolism in patients already receiving glucocorti-
coids. At week 12, significant decreases in levels
of cartilage degeneration markers CTX-II
(p\ 0.01) and CTX-II CRT (p\ 0.001) as well as
the bone formation marker PINP (p\ 0.01)
were observed, and bone degeneration markers
CTX and CTX-I showed no significant changes
with RCI treatment in this population.
Efficacy: Double-Blind Withdrawal Period
At week 24, DAS28-ESR LDA was maintained in
47 of 77 (61.0%) RCI-treated subjects and 32 of
76 (42.1%) placebo-treated subjects (p = 0.019;
Fig. 3b). Mean DAS28-ESR over time during the
double-blind period did not differ significantly
between treatment groups (Fig. 3d). Mean time
to disease activity flare during weeks 12 through
24 was 6.5 weeks (SD, 2.61 weeks) for the pla-
cebo group and 8.2 weeks (SD, 2.92 weeks) for
the RCI group. At week 24, 66 subjects (85.7%)
in the RCI group and 50 (65.8%) in the placebo
group maintained LDA, as defined by CDAI
scores B 10 (p = 0.004; Fig. 3f). A vast majority
of subjects achieved ACR20 and ACR50
responses during the open-label period, and
these responses were maintained through the
double-blind period in both treatment groups;
at week 24 of the double-blind period, ACR70
responses were seen in 47% of RCI-treated
Fig. 2 Subject disposition. aSubjects met withdrawal cri-
teria if they developed a condition that met any of the
study exclusion criteria or failed to meet any inclusion
criteria during the study that was not considered an AE or
if they were noncompliant. AE adverse event, DB double-
blind, LDA low disease activity, LTFU lost to follow-up,
OL open-label, RCI repository corticotropin injection
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Table 1 Subject demographics and baseline characteristics, safety population
Characteristic Part 1: open-label Part 2: double-blind
RCI (n = 259) Placebo (n = 77) RCI (n = 77)
Age, mean (SD), years 51.0 (12.2) 50.9 (11.3) 50.1 (12.2)
Female sex, no. (%) 231 (89.2) 69 (89.6) 67 (87.0)
Race, no. (%)
White 170 (65.6) 53 (68.8) 53 (68.8)
Black or African American 15 (5.8) 2 (2.6) 1 (1.3)
Asian 3 (1.2) 1 (1.3) 0
Americana Indian or Alaska native 40 (15.4) 14 (18.2) 12 (15.6)
Native Hawaiian or other Pacific Islander 0 0 0
Other 31 (12.0) 7 (9.1) 11 (14.3)
Ethnicity, no. (%)
Hispanic or Latino 213 (82.2) 69 (89.6) 73 (94.8)
Country, no. (%)
United States 88 (34.0) 19 (24.7) 19 (24.7)
Mexico 120 (46.3) 46 (59.7) 41 (53.2)
Argentina 24 (9.3) 7 (9.1) 9 (11.7)
Peru 27 (10.4) 5 (6.5) 8 (10.4)
Weight, mean (SD), kg 72.9 (17.0) 72.4 (14.5) 70.8 (15.7)
BMI, mean (SD), kg/m2 28.8 (5.7) 29.0 (5.4) 28.2 (5.7)
Disease duration, mean (SD), years 10.3 (8.0) 9.4 (8.8) 10.1 (6.8)
Prednisone (or equivalent) dose, mean (SD), mg/day 6.3 (5.0) 6.9 (8.7) 5.9 (1.7)
Medical history of note, no. (%) [no. ongoing]
Hypertension 74 (28.6) [73] 20 (26.0) [20] 20 (26.0) [20]
Obesity 6 (2.3) [6] 1 (1.3) [1] 0
Myocardial infarction 2 (0.8) [0] 1 (1.3) [0] 0
Arrhythmia 1 (0.4) [1] 0 0
Cerebrovascular accident 1 (0.4) [0] 0 1 (1.3) [0]
Cerebrovascular disorder 1 (0.4) [0] 1 (1.3) [0] 0
Coronary artery disease 1 (0.4) [1] 0 0
Type 2 diabetes mellitus 1 (0.4) [1] 1 (1.3) [1] 0
Methotrexate use, no. (%)
Prior 253 (97.7) 77 (100.0) 77 (100.0)
Concomitant 248 (95.8) 77 (100.0) 77 (100.0)
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Table 1 continued
Characteristic Part 1: open-label Part 2: double-blind
RCI (n = 259) Placebo (n = 77) RCI (n = 77)
Most common (C 3% of subjects) prior DMARDs, no. (%)
Biologicb 60 (23.2) 7 (9.1) 13 (16.9)
Adalimumab 26 (10.0) 3 (3.9) 4 (5.2)
Etanercept 22 (8.5) 1 (1.3) 4 (5.2)
Abatacept 16 (6.2) 1 (1.3) 6 (7.8)
Certolizumab pegol 13 (5.0) 1 (1.3) 2 (2.6)
Tocilizumab 10 (3.9) 0 2 (2.6)
Infliximab 9 (3.5) 1 (1.3) 2 (2.6)
Nonbiologicc 232 (89.6) 74 (96.1) 71 (92.2)
Hydroxychloroquine 105 (40.5) 26 (33.8) 39 (50.7)
Sulfasalazine 56 (21.6) 19 (24.7) 10 (13.0)
Leflunomide 53 (20.5) 20 (26.0) 12 (15.6)
Chloroquine 33 (12.7) 13 (16.9) 13 (16.9)
Tofacitinib 8 (3.1) 1 (1.3) 3 (3.9)
Most common (C 3% of subjects) concomitant DMARDs, no. (%)
Biologicd 45 (17.4) 9 (11.7) 17 (22.1)
Adalimumab 12 (4.6) 1 (1.3) 1 (1.3)
Certolizumab pegol 9 (3.5) 1 (1.3) 2 (2.6)
Etanercept 9 (3.5) 1 (1.3) 1 (1.3)
Abatacept 8 (3.1) 1 (1.3) 3 (3.9)
Nonbiologice 224 (86.5) 57 (74.0) 59 (76.6)
Hydroxychloroquine 97 (37.5) 25 (32.5) 38 (49.4)
Sulfasalazine 54 (20.9) 19 (24.7) 9 (11.7)
Leflunomide 46 (17.8) 0 0
Chloroquine 33 (12.7) 13 (16.9) 13 (16.9)
DAS28-ESR, mean (SD) 6.3 (1.0) 6.2 (1.0) 6.2 (0.9)
ESR, mean (SD) 43.6 (24.8) 42.0 (22.9) 40.3 (21.5)
DAS28-ESR at week 12, mean (SD) 3.6 (1.4) 2.7 (0.5) 2.8 (0.4)
ESR at week 12, mean (SD) 24.0 (21.5) 15.2 (12.6) 15.8 (12.2)
Tender joint count, mean (SD)f 14.7 (7.1) 13.5 (7.2) 13.5 (6.1)
Swollen joint count, mean (SD)f 10.9 (5.4) 10.1 (4.9) 9.7 (4.3)
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subjects and 42% of subjects who had discon-
tinued RCI (Fig. 3h). At week 24, 23 subjects
(29.9%) in the RCI group and 23 (30.3%) in the
placebo group achieved DAS28-ESR remission
(p = 0.828) in this population with previously
highly active RA. Levels of C-reactive protein
did not change substantially (Figure S1b in the
electronic supplementary material). The mean
number of tender and swollen joints remained
decreased during the double-blind period, with
no significant differences between the RCI and




Improvements on the HAQ-DI, FACIT-F, and
WPAI that were noted during the open-label
period were generally maintained in both
treatment groups throughout the double-blind
period (Figures S3b, S4b, and S5b–e in the elec-
tronic supplementary material). There were no
significant differences between the RCI and
placebo groups on these metrics.
Bone Turnover Markers: Double-Blind
Period
Levels of the osteoclast differentiation marker
sRANKL significantly increased from baseline to
week 12 and week 24 (both p\0.05) in the RCI
Table 1 continued
Characteristic Part 1: open-label Part 2: double-blind
RCI (n = 259) Placebo (n = 77) RCI (n = 77)
HAQ-DIf 1.7 (0.6) 1.7 (0.6) 1.7 (0.5)
FACIT-Ff 22.8 (8.4) 22.6 (9.0) 22.7 (7.7)
BMI body mass index, DAS28 Disease Activity Score with 28 joint count, DMARD disease-modifying antirheumatic drug,
ESR erythrocyte sedimentation rate, FACIT-F Functional Assessment of Chronic Illness Therapy-Fatigue, HAQ-DI Health
Assessment Questionnaire-Disability Index, mITT modified intent-to-treat, RA rheumatoid arthritis, RCI repository cor-
ticotropin injection, SD standard deviation
a North, Central, or South American Indian
b Golimumab, rituximab, clazakizumab, sarilumab, and sirukumab each were taken by\ 3% of subjects
c Filgotinib was taken by\ 3% of subjects
d Golimumab, infliximab, and certolizumab each were taken by\ 3% of subjects
e Tofacitinib was taken by\ 3% of subjects
f Data are from the mITT population
cFig. 3 Key efficacy outcomes (mITT population). Pro-
portion of subjects achieving (part 1, open-label period)
and maintaining (part 2, double-blind period) key efficacy
milestones: LDA (DAS28-ESR\ 3.2) (a, b), CDAI B 10
(e, f), and ACR criteria (g, h). Mean DAS28-ESR over
time (c, d). a Primary efficacy endpoint. *p B0.05;
**p B 0.01; ***p B 0.001; ****p\ 0.0001 from one-sample
binomial test (open-label period) or Pearson’s Chi-square
test (double-blind period). p values denote differences from
baseline for the open-label period and from placebo for the
double-blind period. Percentages above bars are rounded to
the nearest whole number. Error bars are 95% confidence
intervals unless otherwise noted. Note: The proportions of
subjects meeting ACR50 and ACR70 criteria during part 2
were not prespecified endpoints and were evaluated post
hoc. ACR American College of Rheumatology, CDAI
Clinical Disease Activity Index, DAS28-ESR Disease
Activity Score with 28 joint count erythrocyte sedimen-
tation rate, LDA low disease activity, mITT modified
intent-to-treat, RCI repository corticotropin injection, SD
standard deviation
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group, but not in the placebo group (Table 2).
All other bone turnover markers remained
stable.
Safety
During the open-label period, 43 subjects
(16.6%) reported treatment-related AEs; nine
subjects (11.7%) in the RCI group and ten
(13.0%) in the placebo group reported treat-
ment-related AEs during the double-blind per-
iod (Table 3). Adverse events that are typically
associated with corticosteroid use (e.g., hyper-
tension, hyperglycemia, headache, weight gain,
edema) were low in incidence or not reported at
all. Three subjects (1.2%) reported serious AEs,
all during the open-label period. One case each
of chest pain and craniocerebral injury were
considered unrelated to treatment. One case of
pneumonia was considered possibly related to
treatment; RCI therapy was discontinued, and
the patient recovered. No subjects died during
the study.
Table 2 Bone turnover markers, mITT population
















Baselinea 4.79 (2.09) 0.39 (0.21) 3.46 (2.31) 452.4 (325.4) 4.71 (1.80) 52.23 (28.21) 2057.70 (3592.90)
Week 12b 4.76 (1.93) 0.39 (0.21) 2.99c (2.17) 362.5d (273.1) 4.68 (1.98) 47.37c (26.21) 2107.55 (3794.56)
Double-blind period
Baseline
RCIe 4.77 (1.89) 0.44 (0.22) 3.69 (2.47) 463.7 (316.9) 4.86 (1.83) 54.76 (28.79) 1519.42 (2378.26)
Placebof 4.58 (1.98) 0.38 (0.18) 3.61 (2.42) 460.5 (368.3) 4.65 (1.78) 52.46 (26.38) 2416.34 (3825.88)
Week 12
RCIg 4.58 (1.40) 0.45 (0.23) 2.93 (2.19) 368.0 (228.6) 4.79 (2.23) 51.19 (29.06) 2451.77h (4417.55)
Placeboi 4.61 (1.63) 0.40 (0.21) 3.21 (2.36) 382.5 (257.5) 4.73 (1.89) 48.69 (25.07) 2358.63 (4401.72)
Week 24
RCIj 4.79 (2.76) 0.44 (0.20) 3.13 (1.87) 339.4 (189.7) 4.93 (2.04) 54.34 (40.08) 2938.96k (5006.25)
Placebol 4.47 (1.68) 0.41 (0.20) 3.27 (2.05) 391.6 (236.0) 5.12 (2.12) 53.10 (26.16) 2105.64 (4116.93)
Bolded values are statistically significant
CTX C-terminal crosslinking telopeptide, CTX-I C-terminal crosslinking telopeptide of type I collagen, CTX-II C-terminal
crosslinking telopeptide of type II collagen, CTX-II CRT creatinine-adjusted CTX-II, mITT modified intent-to-treat, OPG
osteoprotegerin, PINP N-terminal peptide of type I collagen, RCI repository corticotropin injection, SD standard deviation,
sRANKL soluble receptor activator of nuclear kappa B ligand
a CTX, n = 251; CTX-I and OPG, n = 254; CTX-II, n = 190; CTX-II CRT, n = 183; PINP, n = 257; sRANKL, n = 250
b CTX, n = 238; CTX-I, n = 243; CTX-II, n = 159; CTX-II CRT, n = 153; OPG, n = 239; PINP, n = 246; sRANKL,
n = 231
c p\ 0.01, one-sample t test for week 12 versus baseline
d p\ 0.001, one-sample t test for week 12 versus baseline
e CTX, CTX-I, and PINP, n = 75; CTX-II, n = 59; CTX-II CRT, n = 57; OPG and sRANKL, n = 73
f CTX, n = 72; CTX-I, OPG, and sRANKL, n = 75; CTX-II, n = 59; CTX-II CRT, n = 57; PINP, n = 76
g CTX, CTX-I, and PINP, n = 75; CTX-II, n = 66; CTX-II CRT, n = 64; OPG, n = 74; sRANKL, n = 72
h p\ 0.05, two-sample t test for RCI time point versus baseline
i CTX, n = 73; CTX-I, OPG, and PINP, n = 74; CTX-II, n = 62; CTX-II CRT, n = 61; sRANKL, n = 71
j CTX, CTX-I, and PINP, n = 75; CTX-II and CTX-II CRT, n = 63; OPG, n = 74; sRANKL, n = 70
k p\ 0.01, two-sample t test for RCI time point versus baseline
l CTX, CTX-I, OPG, and PINP, n = 65; CTX-II, n = 46; CTX-II CRT, n = 45; sRANKL, n = 61
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DISCUSSION
These results support the efficacy of RCI in
patients with continued highly active RA
despite treatment with prednisone and one or
two DMARDs, which could include a bDMARD.
Despite a mean baseline DAS28-ESR of 6.3, 63%
of patients achieved DAS28-ESR\ 3.2 by week
12, with a statistically significant percentage
achieving LDA by week 8. Thus, the study’s
primary endpoint was met (Fig. 3a). These
results were confirmed by the proportions of
subjects who achieved CDAI B 10 (Fig. 3e) and
Table 3 Summary of AEs, safety population
Part 1 (open-label period)
AE No. (%) of
patients
RCI (n = 259)
Any AEa 98 (37.8)
Anemia 5 (1.9)






Upper respiratory tract infection 4 (1.5)
Urinary tract infection 10 (3.9)
AE resulting in study drug
withdrawal
3 (1.2)
Serious AE 3 (1.2)
Serious infectious event 1 (0.4)
Opportunistic infections
Herpes zoster 1 (0.4)
Tuberculosis 0
Death 0
Part 2 (double-blind period)





Any AEa 31 (40.3) 25 (32.5)
Anemia 2 (2.6) 2 (2.6)
Back pain 0 2 (2.6)
Diarrhea 3 (3.9) 1 (1.3)
Dizziness 1 (1.3) 1 (1.3)




2 (2.6) 1 (1.3)
Table 3 continued
Part 2 (double-blind period)





Headache 5 (6.5) 5 (6.5)
Hyperglycemia 2 (2.6) 3 (3.9)
Hypertension 0 3 (3.9)
Influenza 1 (1.3) 1 (1.3)
Nasopharyngitis 2 (2.6) 2 (2.6)




Urinary tract infection 3 (3.9) 2 (2.6)
AE resulting in study
drug withdrawal
1 (1.3) 0
Serious AE 0 0
Serious infectious event 0 0
Opportunistic infections
Herpes zoster 0 0
Tuberculosis 0 0
Death 0 0
AE adverse event, RCI repository corticotropin injection
a AEs reported in C 1.5% of subjects in part 1 or in either
group in part 2 are listed below
b Refers to glycosylated hemoglobin values[ 6.5%
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ACR20, ACR50, and ACR70 responses (Fig. 3g)
during the open-label period.
During the double-blind period, DAS28-ESR
LDA was maintained in almost two-thirds of
subjects who continued RCI. Of impor-
tance,[ 40% of patients who withdrew from
RCI to placebo maintained LDA for an addi-
tional 12 weeks (Fig. 3b). These results suggest
that patients with high disease activity despite
treatment with glucocorticoids and a csDMARD
(with or without a bDMARD) or a bDMARD as
monotherapy may have a clinically meaningful
decrease in disease activity with RCI treatment
for a period of 3 months, which may be main-
tained even after RCI treatment withdrawal.
Interestingly, when LDA was assessed by
CDAI B 10 (Fig. 3d), 86% of subjects who con-
tinued on RCI maintained LDA, and almost
two-thirds of subjects who withdrew RCI
maintained LDA. Disparity in the durability of
response as assessed by DAS28-ESR versus by
CDAI is most likely explained by differences in
the contribution of various elements to these
metrics. Although both the DAS28 and the
CDAI assess tender and swollen joints, these
factors are given equal weight in calculation of
CDAI scores, whereas tender joint counts are
given twice the weight of swollen joints in cal-
culation of the DAS28-ESR [25, 33]. Impor-
tantly, the CDAI does not assess ESR, an acute
phase reactant, whereas the DAS28-ESR does.
Achievement and maintenance of remission,
or at least LDA, should be the primary approach
for RA, but assessment of physical functioning,
disability, and other health outcomes also pro-
vides important information for the overall
evaluation of a drug’s benefit. During the open-
label period, improvements were seen in several
patient-reported outcomes assessing disability
(HAQ-DI), fatigue (FACIT-F), and work/activity
(WPAI). These improvements were generally
maintained during the double-blind withdrawal
period in both treatment groups, which further
supports the suggestion that the benefits of RCI
may be maintained for some time after treat-
ment is discontinued.
No unexpected safety signals were observed
during the study. The three serious AEs reported
in patients receiving RCI were consistent with
those previously reported with RCI therapy. The
incidences of AEs commonly associated with
corticosteroids were low and typically similar in
the RCI and placebo groups, which suggests the
possibility of minimal additional steroidal
effects of RCI in patients already on glucocor-
ticoids. One might expect a greater incidence of
common corticosteroid-associated AEs if RCI
therapy were continued indefinitely, but
extension studies and/or registries would be
needed to evaluate the safety of long-term RCI
therapy. Markers of bone turnover were mostly
stable during both study periods, indicating no
pronounced additional effect of RCI on bone
metabolism in patients who had been receiving
5 to 10 mg/day of prednisone (or equivalent)
for C 4 weeks. In the open-label period, carti-
lage degeneration markers showed a significant
decrease from baseline at week 12; although the
bone formation marker PINP significantly
decreased, this may not be indicative of bone
loss, especially because bone degeneration
markers remained stable. During the double-
blind period, levels of osteoclast marker sRANKL
significantly increased from baseline to weeks
12 and 24 in the RCI group but not the placebo
group. However, this may not suggest evidence
of bone damage, as bone degeneration marker
levels remained stable. The role of RCI and bone
turnover in a population already receiving glu-
cocorticoids over a prolonged period still needs
to be evaluated.
Results from this study suggest a role for RCI
in treating patients who have active RA with at
least moderate disease activity despite maximal
treatment with DMARDs, whether csDMARDs
or bDMARDs, and who are also being treated
with glucocorticoids. In previous studies,
including the COBRA study [34] and other
similar trials, high- or moderate-dose glucocor-
ticoids were used in the initiation of therapy
(with subsequent tapering) to quickly obtain
disease control. In contrast, RCI was used not as
initial therapy but rather as rescue therapy in
the current study while low/moderate-dose
glucocorticoids were maintained. Assuming the
patient has been maximally treated with
DMARDs, a potential treatment scenario might
involve 3 months of RCI therapy with the aim
of achieving remission or LDA. Results from this
study suggest that such patients with
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recalcitrant disease may respond well to RCI
therapy and that some patients will maintain
LDA after discontinuation of RCI therapy. Thus,
it is at the discretion of the physician whether
to discontinue RCI therapy at 3 months, with
subsequent monitoring to assess whether
response is maintained. For patients who
develop a flare after RCI discontinuation, the
consideration of additional RCI therapy for
flares when they occur may be reasonable if
long-term safety findings support such an
approach. The effects of long-term RCI therapy
on bone health and other aspects of safety are
unclear and require further study, but the
results from this study suggest that RCI could be
used in an intermittent manner for many
patients without significant concerns about
general safety or bone loss. For patients who
have flares shortly after discontinuation of RCI
therapy, the risk–benefit for prolonged use of
RCI still needs to be defined.
This study has some notable limitations.
Although we used a study design that has pre-
viously been employed successfully [35], the
primary endpoint was measured in the open-
label period, during which all subjects knew
that they were being treated with RCI. The
response observed for this endpoint in this
population with recalcitrant disease was higher
than expected, which could, in part, be a result
of the study design (i.e., a placebo effect).
However, it would be unusual for a placebo
effect to manifest after 8 weeks, as it was in this
study (Fig. 3a, e). In addition, the vast majority
([80%) of study participants were of Hispanic
or Latino ethnicity, which may limit extrapo-
lation of the results to the general population. It
is also worth noting that patients with other
rheumatic autoimmune diseases, clinically sig-
nificant infections, or malignancies were
excluded from the study. Caution should be
observed in extrapolating the study’s safety
results to such populations. Also, bone density
testing was not performed in this study but
would be reasonable to evaluate in future stud-
ies, considering the association between gluco-
corticoid therapy and the development of
osteoporosis. Finally, participants in the current
study had highly active RA despite treatment
with DMARDs and glucocorticoids, and changes
in these baseline therapies were not allowed
during the study in order to properly assess the
rescue effects of RCI. Current guidelines from
EULAR [36] and ACR [4] recommend that glu-
cocorticoids be used at the lowest possible dose
and tapered as soon as feasible. Future studies
with additional treatment arms wherein taper-
ing of glucocorticoids and/or DMARD adjust-
ments are allowed may be warranted.
Despite these limitations, the randomized,
double-blind, placebo-controlled withdrawal
period of this study provided a more rigorous
assessment of the efficacy and safety of RCI.
CONCLUSIONS
The results of this study of patients who had
active RA despite corticosteroid/DMARD ther-
apy show that patients can achieve LDA as early
as week 8. By week 12, more than half of the
subjects achieved LDA, which was maintained
with an additional 12 weeks of treatment.
Importantly, many subjects who achieved LDA
with RCI therapy and then discontinued RCI
use during the withdrawal period were able to
maintain LDA for the subsequent 3 months,
which may suggest sustained durability of RCI
therapy. No new unexpected safety signals were
noted, and markers of bone turnover were
mostly stable, suggesting that RCI does not
cause further bone loss in patients with active
RA previously treated with glucocorticoids.
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